Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study - PubMed (original) (raw)
Clinical Trial
Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study
Ian H de Boer et al. J Am Soc Nephrol. 2007 Jan.
Abstract
Weight gain and central obesity are associated with insulin resistance, hypertension, and dyslipidemia in type 1 diabetes. These metabolic abnormalities are risk factors for kidney disease in the general population, but data addressing the relationship of central obesity with kidney disease in type 1 diabetes are limited. Whether waist circumference is associated with incident microalbuminuria and change in creatinine clearance was examined among 1279 participants who had type 1 diabetes and were enrolled in the Epidemiology of Diabetes Interventions and Complications Study, the observational extension of the Diabetes Control and Complications Trial (DCCT). Ninety-three of 1105 participants with normal albumin excretion rate (AER) at DCCT closeout developed incident microalbuminuria over 5.8 yr of follow-up. The hazard ratio for incident microalbuminuria that was associated with each 10-cm greater waist circumference at DCCT closeout was 1.34 (95% confidence interval 1.07 to 1.68), after adjustment for DCCT closeout age, gender, duration of diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER. This increased risk was modestly attenuated when additional adjustment was made for levels of BP and serum lipids. Creatinine clearance declined by an average of 0.34 ml/min per 1.73 m2 each yr over 8 yr of follow-up. Greater rate of decline in creatinine clearance was associated with greater age, conventional insulin therapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not with waist circumference. In conclusion, waist circumference predicts the subsequent development of microalbuminuria in type 1 diabetes. In contrast, no association of waist circumference with decline in creatinine clearance was observed.
Figures
Figure 1
Unadjusted cumulative incidence of microalbuminuria by gender-specific quartile of waist circumference and Diabetes Control and Complications Trial (DCCT) treatment group. ■, conventional insulin therapy; , intensive insulin therapy.
Figure 2
Adjusted relative risk for incident microalbuminuria by gender-specific quartile of waist circumference. Risk is presented relative to that of women in the category of smallest waist circumference (reference group), adjusted for age, race, duration of diabetes, treatment group, smoking status, glycosylated hemoglobin, and albumin excretion rate, each measured at DCCT closeout. Gender-specific waist quartiles are plotted at the mean waist circumference for each group.
Similar articles
- Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA. 2003 Oct 22;290(16):2159-67. doi: 10.1001/jama.290.16.2159. JAMA. 2003. PMID: 14570951 Free PMC article. - Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
de Boer IH; DCCT/EDIC Research Group. de Boer IH, et al. Diabetes Care. 2014;37(1):24-30. doi: 10.2337/dc13-2113. Diabetes Care. 2014. PMID: 24356594 Free PMC article. Clinical Trial. - Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.
DCCT/EDIC research group. DCCT/EDIC research group. Lancet Diabetes Endocrinol. 2014 Oct;2(10):793-800. doi: 10.1016/S2213-8587(14)70155-X. Epub 2014 Jul 17. Lancet Diabetes Endocrinol. 2014. PMID: 25043685 Free PMC article. Clinical Trial. - The relationship between glucose control and the development of diabetic nephropathy in type I diabetes.
Molitch ME. Molitch ME. Semin Nephrol. 1997 Mar;17(2):101-13. Semin Nephrol. 1997. PMID: 9148376 Review. - Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
Donnelly R, Yeung JM, Manning G. Donnelly R, et al. J Hypertens Suppl. 2003 Mar;21(1):S7-12. J Hypertens Suppl. 2003. PMID: 12769161 Review.
Cited by
- Piperazine ferulate inhibits diabetic nephropathy by suppressing AGE/RAGE-mediated inflammatory signaling in rats and podocytes.
Zhang XM, Min XR, Xie HX, Jiang YN, Rui YX, Li B, Zeng N, Liu R. Zhang XM, et al. Front Pharmacol. 2024 Aug 1;15:1394369. doi: 10.3389/fphar.2024.1394369. eCollection 2024. Front Pharmacol. 2024. PMID: 39148540 Free PMC article. - What will we see in diabetes in the next 10 years?
Bloomgarden ZT. Bloomgarden ZT. J Diabetes. 2024 Jun;16(6):e13594. doi: 10.1111/1753-0407.13594. J Diabetes. 2024. PMID: 38890754 Free PMC article. No abstract available. - Sex disparities in the association between serum cotinine and chronic kidney disease.
Song J, Wang P, Li H. Song J, et al. Tob Induc Dis. 2024 Apr 29;22. doi: 10.18332/tid/185965. eCollection 2024. Tob Induc Dis. 2024. PMID: 38686043 Free PMC article. - An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis.
Risi R, Vidal-Puig A, Bidault G. Risi R, et al. J Endocrinol. 2024 May 15;262(1):e230313. doi: 10.1530/JOE-23-0313. Print 2024 Jul 1. J Endocrinol. 2024. PMID: 38642584 Free PMC article. Review. - Cigarette smoking and progression of kidney dysfunction: a longitudinal cohort study.
Matsumoto A, Nagasawa Y, Yamamoto R, Shinzawa M, Yamazaki H, Shojima K, Shinmura K, Isaka Y, Iseki K, Yamagata K, Narita I, Konta T, Kondo M, Tsuruya K, Kasahara M, Shibagaki Y, Fujimoto S, Asahi K, Watanabe T, Moriyama T. Matsumoto A, et al. Clin Exp Nephrol. 2024 Aug;28(8):793-802. doi: 10.1007/s10157-024-02487-6. Epub 2024 Apr 6. Clin Exp Nephrol. 2024. PMID: 38581622
References
- US Renal Data System . USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda: 2004.
- Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47:1703–1720. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HL004136/HL/NHLBI NIH HHS/United States
- 5 K12 RR023265-03/RR/NCRR NIH HHS/United States
- T32 DK007247/DK/NIDDK NIH HHS/United States
- N01 DK062204-007/DK/NIDDK NIH HHS/United States
- DK02456/DK/NIDDK NIH HHS/United States
- DK007247/DK/NIDDK NIH HHS/United States
- M01-RR01066/RR/NCRR NIH HHS/United States
- M01 RR001066/RR/NCRR NIH HHS/United States
- P01 DK002456/DK/NIDDK NIH HHS/United States
- DK599445/DK/NIDDK NIH HHS/United States
- K12 RR023265/RR/NCRR NIH HHS/United States
- K30 HL004136/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical